BHC 주식 개요 는 미국 및 전 세계에서 다양한 전문 제약 및 의료 기기 회사로 운영되고 있습니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Bausch Health Companies Inc. 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Bausch Health Companies 과거 주가 현재 주가 US$10.85 52주 최고치 US$15.43 52주 최저치 US$5.45 베타 0.69 1개월 변경 -4.74% 3개월 변경 사항 -2.69% 1년 변경 사항 2.07% 3년 변화 -68.95% 5년 변화 -71.60% IPO 이후 변화 1,695.85%
최근 뉴스 및 업데이트
Bausch Health Companies Inc. Appoints Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D Dec 02
Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada Nov 19
Forecast breakeven date pushed back to 2025 Nov 03
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 01
Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA Oct 28
Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 10 더 많은 업데이트 보기
Bausch Health Companies Inc. Appoints Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D Dec 02
Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada Nov 19
Forecast breakeven date pushed back to 2025 Nov 03
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 01
Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA Oct 28
Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 10
Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel Sep 11
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 02
Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024 Aug 01 Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma
Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 12
Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024 May 18
Bausch Health Companies Inc. Approves Directorate Appointments May 16
First quarter 2024 earnings: EPS misses analyst expectations May 03
Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan Apr 13
Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 12
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults Apr 03
Insufficient new directors Apr 01
Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma Mar 06
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 23
Bausch Health Companies Inc., Annual General Meeting, May 14, 2024 Feb 21 Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024
Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel Jan 31
Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute Jan 09
Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis Dec 22
Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan Dec 19
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 02
FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older Oct 21
Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 13 Bausch Health Companies Inc. Announces Executive Changes
Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults Sep 14
Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc Sep 08
Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc Sep 06
Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023 Aug 04
Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022) Aug 04
Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc Jul 27
Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 14
New major risk - Financial position Jul 01
Forecast to breakeven in 2025 May 10
First quarter 2023 earnings: EPS misses analyst expectations May 06
Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023 May 05
Forecast breakeven date pushed back to 2025 Apr 18
Full year 2022 earnings: EPS misses analyst expectations Feb 24
Investor sentiment improves as stock rises 23% Feb 16
Bausch Health Companies Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 02
Investor sentiment improved over the past week Jan 06
Bausch Health Companies Inc. Announces Availability of ARAZLOTM Dec 23
Investor sentiment deteriorated over the past week Dec 22
Investor sentiment improved over the past week Dec 02
Third quarter 2022 earnings: EPS exceeds analyst expectations Nov 04
Bausch Health Companies Inc. Revises Consolidated Earnings Guidance for the Full Year 2022 Nov 04
Bausch Health Companies Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 14
Bausch Health Companies Inc. and Glenmark Specialty S.A. Announce the Approval of RYALTRIS® in Canada Sep 23
Insider recently sold CA$932k worth of stock Sep 21 Bausch Health Companies Inc.(TSX:BHC) dropped from FTSE All-World Index (USD)
Bausch Health Companies Inc. Responds to Norwich Pharmaceuticals Tentative FDA Approval for 200 mg Rifaximin Sep 10
Investor sentiment improved over the past week Sep 07
Investor sentiment improved over the past week Aug 16 Bausch Health Companies Inc. to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 10 Bausch Health Companies Inc. Announces Unaudited Impairment Results for the Quarter Ended June 30, 2022
Insufficient new directors Jul 31
Bausch Health Companies Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 28
Insufficient new directors Jul 01
Bausch Health Companies Inc. Announces Updates to Its Board of Directors Jun 24
Bausch Health Companies Inc. Appoints John S. Barresi as the Company’s Senior Vice President, Controller and Chief Accounting Officer Jun 01
Bausch Health Companies Inc. Provides Revenue Guidance for the Year Full Year 2022 May 12
Bausch Health Companies Inc. Announces Management Changes May 08
Bausch Health Companies Inc. to Report Q1, 2022 Results on May 10, 2022 May 02
Bausch Health Companies Inc., Annual General Meeting, Jun 14, 2022 Apr 02
Full year 2021 earnings: EPS misses analyst expectations Feb 26 Bausch Health Companies Inc. Provides Earnings Guidance for the Year 2022
Bausch Health, Canada Announces Availability through Pharmacies Across Canada of its New Prescription Treatment TRULANCE Feb 09
Bausch Health Companies Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 04
Bausch Health Companies Inc. has filed an IPO. Jan 15
Bausch Health Companies Inc. Announces New Post-Hoc Analysis of Pooled Results on the Safety and Efficacy of A Single Dose of Relistor Injection Dec 23
Insider recently bought CA$1.9m worth of stock Dec 03
Third quarter 2021 earnings released: EPS US$0.52 (vs US$0.20 in 3Q 2020) Nov 03
Independent Director recently bought CA$314k worth of stock Aug 07
Bausch Health Companies Inc. Revises Earnings Guidance for the Year 2021 Aug 05
Second quarter 2021 earnings released: US$1.66 loss per share (vs US$0.92 loss in 2Q 2020) Aug 04
Abu Dhabi Developmental Holding Company PJSC completed the acquisition of Amoun Pharmaceutical Company S.A.E. from Bausch Health Companies Inc. (NYSE:BHC) and others. Aug 04
Bausch + Lomb Expands Parameters for Bausch + Lomb Ultra® Multifocal for Astigmatism Contact Lenses Jun 24
Independent Director David Hale has left the company Jun 22
CFO & Executive VP recently sold CA$655k worth of stock Jun 16
Bausch Health and Clearside Biomedical Announce U.S. FDA Filing Acceptance for XIPERE (Triamcinolone Acetonide Suprachoroidal Injectable Suspension) Jun 03
Independent Director recently sold CA$425k worth of stock May 30
Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Four Scientific Poster Presentations Featuring Data for XIFAXAN May 18
Bausch Health Companies Inc. Announces New Data from the National Eye Reaffirms the Clinical Outcomes of the AREDS2 Study May 13
First quarter 2021 earnings released: US$1.71 loss per share (vs US$0.43 loss in 1Q 2020) May 07
Bausch Health Companies Inc. Reiterates Revenue Guidance for the Full Year of 2021 May 05
Bausch Health Reportedly Explores Eye-Care Unit Sale Apr 29 주주 수익률 BHC CA Pharmaceuticals CA 마켓 7D 1.3% 1.2% 1.0% 1Y 2.1% -30.7% 15.9%
전체 주주 수익률 보기
수익률 대 산업: BHC 지난 1년 동안 -30.7 %를 반환한 Canadian Pharmaceuticals 산업을 초과했습니다.
수익률 대 시장: BHC 지난 1년 동안 15.9 %를 반환한 Canadian 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is BHC's price volatile compared to industry and market? BHC volatility BHC Average Weekly Movement 7.0% Pharmaceuticals Industry Average Movement 12.1% Market Average Movement 8.2% 10% most volatile stocks in CA Market 17.3% 10% least volatile stocks in CA Market 3.0%
안정적인 주가: BHC 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: BHC 의 주간 변동성 ( 7% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 는 미국 및 전 세계에서 다양한 전문 제약 및 의료 기기 회사로 운영되고 있습니다. 주로 위장병학, 간학, 신경학, 피부과, 국제 의약품, 일반 의약품, 미용 의료 기기, 눈 건강 분야에서 다양한 제품을 개발, 제조 및 판매합니다. 이 회사는 5개 부문으로 운영됩니다: 살릭스, 인터내셔널, 솔타 메디컬, 다각화, 바우쉬+롬입니다.
자세히 보기 Bausch Health Companies Inc. 기본 사항 요약 Bausch Health Companies 의 수익과 매출은 시가총액과 어떻게 비교하나요? BHC 기본 통계 시가총액 CA$4.03b 수익(TTM ) -CA$256.55m 수익(TTM ) CA$13.65b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) BHC 손익 계산서(TTM ) 수익 US$9.47b 수익 비용 US$2.76b 총 이익 US$6.71b 기타 비용 US$6.89b 수익 -US$178.00m
주당 순이익(EPS) -0.48 총 마진 70.87% 순이익 마진 -1.88% 부채/자본 비율 -8,887.2%
BHC 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/27 05:45 장 마감 주가 2024/12/24 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Bausch Health Companies Inc. 46 애널리스트 중 7 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Raghuram Selvaraju Aegis Capital Corporation Douglas Tsao Barclays Ardalan Arfaei BMO Capital Markets Equity Research
43 더 많은 분석가 보기 
